These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32124135)

  • 1. Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer.
    Masuda T; Fujimoto H; Teranaka R; Kuroda M; Aoyagi Y; Nagashima T; Sangai T; Takada M; Nakagawa A; Kubota Y; Yokote K; Ohtsuka M
    Breast Cancer Res Treat; 2020 Apr; 180(3):625-634. PubMed ID: 32124135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models.
    Teranaka R; Fujimoto H; Masuda T; Kuroda M; Aoyagi Y; Nagashima T; Takada M; Sakakibara J; Yamada H; Yamamoto H; Kubota Y; Ohtsuka M
    Breast Cancer; 2023 Nov; 30(6):1018-1027. PubMed ID: 37612442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib.
    Chakraborty AK; Zerillo C; DiGiovanna MP
    Breast Cancer Res Treat; 2015 Aug; 152(3):533-44. PubMed ID: 26195122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
    Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
    Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
    Bloom MJ; Jarrett AM; Triplett TA; Syed AK; Davis T; Yankeelov TE; Sorace AG
    BMC Cancer; 2020 Apr; 20(1):359. PubMed ID: 32345237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity.
    Duong MN; Cleret A; Matera EL; Chettab K; Mathé D; Valsesia-Wittmann S; Clémenceau B; Dumontet C
    Breast Cancer Res; 2015 Apr; 17(1):57. PubMed ID: 25908175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells.
    Xiong L; Ding L; Ning H; Wu C; Fu K; Wang Y; Zhang Y; Liu Y; Zhou L
    Oncotarget; 2016 Sep; 7(36):57737-57751. PubMed ID: 27363028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
    Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
    Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
    BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2.
    Kim H; Danishmalik SN; Hwang H; Sin JI; Oh J; Cho Y; Lee H; Jeong M; Kim SH; Hong HJ
    Cancer Gene Ther; 2016 Oct; 23(10):341-347. PubMed ID: 27632934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer.
    Su F; Zhu S; Ruan J; Muftuoglu Y; Zhang L; Yuan Q
    Oncotarget; 2016 Jan; 7(4):4142-54. PubMed ID: 26716652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
    Kato Y; Ohishi T; Yamada S; Itai S; Takei J; Sano M; Nakamura T; Harada H; Kawada M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2019 Aug; 38(4):157-161. PubMed ID: 31199696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.
    Doyle HA; Koski RA; Bonafé N; Bruck RA; Tagliatela SM; Gee RJ; Mamula MJ
    Cancer Immunol Immunother; 2018 Oct; 67(10):1559-1569. PubMed ID: 30056598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
    Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
    Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness.
    Molina-Crespo Á; Cadete A; Sarrio D; Gámez-Chiachio M; Martinez L; Chao K; Olivera A; Gonella A; Díaz E; Palacios J; Dhal PK; Besev M; Rodríguez-Serrano M; García Bermejo ML; Triviño JC; Cano A; García-Fuentes M; Herzberg O; Torres D; Alonso MJ; Moreno-Bueno G
    Clin Cancer Res; 2019 Aug; 25(15):4846-4858. PubMed ID: 31064780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.
    Frank RT; Edmiston M; Kendall SE; Najbauer J; Cheung CW; Kassa T; Metz MZ; Kim SU; Glackin CA; Wu AM; Yazaki PJ; Aboody KS
    PLoS One; 2009 Dec; 4(12):e8314. PubMed ID: 20016813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
    Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
    Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.